Cellectis S.A. ( (CLLS) ) has released its Q2 earnings. Here is a breakdown of the information Cellectis S.A. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cellectis S.A. is a clinical-stage biotechnology company that leverages its innovative gene-editing platform to develop cell and gene therapies, focusing on allogeneic CAR T immunotherapies for oncology. The company operates in the biotechnology sector, with headquarters in Paris and additional locations in New York and Raleigh, NC.
In its second quarter 2025 financial report, Cellectis highlighted significant advancements in its clinical programs and strategic partnerships. The company is preparing to launch a pivotal Phase 2 trial for its lasme-cel (UCART22) therapy in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and continues to progress its eti-cel (UCART20x22) study in non-Hodgkin lymphoma. Additionally, Cellectis is advancing its collaboration with AstraZeneca on several gene therapy programs.
Financially, Cellectis reported a consolidated net loss of $41.9 million for the first half of 2025, a significant increase from the previous year’s loss. This was primarily due to a $36.1 million shift from a net financial gain to a net financial loss. Despite this, the company saw a substantial increase in revenues, driven by progress in its AstraZeneca collaboration, which contributed to a $14.2 million rise in total revenues and other income.
The company’s cash reserves stood at $230 million as of June 30, 2025, providing a financial runway into the second half of 2027. Cellectis plans to focus its spending on advancing its product pipeline, including manufacturing and clinical trial expenses for its key therapies.
Looking ahead, Cellectis remains committed to advancing its clinical programs and strategic partnerships. The company is poised to initiate a pivotal Phase 2 trial for lasme-cel and anticipates further developments in its ongoing research collaborations, positioning itself for potential future growth in the gene therapy market.